WisdomTree BioRevolution Fund(WDNA · ETF)
ETF quote, holdings, sector allocation, technicals, and options analytics.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Snapshot
$18.07
- 52-Week Range
- $13.00 – $19.10
- YTD
- +6.80%
- IV Rank (30D)
- 6.1
- Straddle Price
- $2.00
- P/C Vol Ratio
- 0.00
Info
WisdomTree BioRevolution Fund (WDNA) ETF
- Exchange
- BATS
- Inception
- 2021-06-01
- Has Options
- Yes
ETF Profile
holdings as of 2026-06-30
Holdings
87
AUM
$2.5M
Provider
WisdomTree
Inception
2021-06-01
Exchange
BATS
Data As Of
2026-06-30
Expense Ratio
—
Dividend Yield
4.28%
Distribution
Annual
Recent distributions
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2025-12-26 | 2025-12-30 | $0.7705 | CD |
| 2024-12-26 | 2024-12-30 | $0.1071 | CD |
| 2023-12-22 | 2023-12-28 | $0.1350 | CD |
| 2022-12-23 | 2022-12-29 | $0.0653 | CD |
| 2021-12-27 | 2021-12-30 | $0.0246 | CD |
Asset Allocation
Top Holdings
top 50 of 87 holdings
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| — | DREY INST PREF GOV MM-M | 6.87% | Short-term investment | US |
| GPCR | Structure Therapeutics Inc | 3.21% | Equity (common) | US |
| LLY | Eli Lilly & Co | 3.13% | Equity (common) | US |
| NTRA | Natera Inc | 2.93% | Equity (common) | US |
| JNJ | Johnson & Johnson | 2.68% | Equity (common) | US |
| MRNA | Moderna Inc | 2.66% | Equity (common) | US |
| STOK | Stoke Therapeutics Inc | 2.49% | Equity (common) | US |
| PFE | Pfizer Inc | 2.42% | Equity (common) | US |
| UTHR | United Therapeutics Corp | 2.32% | Equity (common) | US |
| RGNX | REGENXBIO Inc | 2.30% | Equity (common) | US |
| BNTX | BioNTech SE | 2.26% | Equity (common) | DE |
| AMGN | Amgen Inc | 2.21% | Equity (common) | US |
| IONS | Ionis Pharmaceuticals Inc | 2.20% | Equity (common) | US |
| FOLD | Amicus Therapeutics Inc | 2.19% | Equity (common) | US |
| VALU | Novo Nordisk A/S | 2.17% | Equity (common) | DK |
| AZN | AstraZeneca PLC | 2.15% | Equity (common) | GB |
| BEAM | Beam Therapeutics Inc | 2.14% | Equity (common) | US |
| VALU | CRISPR Therapeutics AG | 2.09% | Equity (common) | CH |
| VALU | Novonesis Novozymes B | 2.03% | Equity (common) | DK |
| IMNM | Immunome Inc | 1.85% | Equity (common) | US |
| GILD | Gilead Sciences Inc | 1.74% | Equity (common) | US |
| EXAS | Exact Sciences Corp | 1.59% | Equity (common) | US |
| TWST | Twist Bioscience Corp | 1.56% | Equity (common) | US |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.54% | Equity (common) | US |
| KRYS | Krystal Biotech Inc | 1.53% | Equity (common) | US |
| VALU | Novartis AG | 1.52% | Equity (common) | CH |
| VRTX | Vertex Pharmaceuticals Inc | 1.39% | Equity (common) | US |
| TXG | 10X Genomics Inc | 1.39% | Equity (common) | US |
| GMAB | Genmab A/S | 1.28% | Equity (common) | DK |
| AGIO | Agios Pharmaceuticals Inc | 1.27% | Equity (common) | US |
| VALU | Roivant Sciences Ltd | 1.27% | Equity (common) | US |
| VCYT | Veracyte Inc | 1.20% | Equity (common) | US |
| CTVA | Corteva Inc | 1.18% | Equity (common) | US |
| REGN | Regeneron Pharmaceuticals Inc | 1.16% | Equity (common) | US |
| VALU | uniQure NV | 1.13% | Equity (common) | NL |
| ARGX | Argenx SE | 1.09% | Equity (common) | NL |
| VALU | Bunge Global SA | 1.09% | Equity (common) | US |
| BMRN | BioMarin Pharmaceutical Inc | 1.09% | Equity (common) | US |
| VALU | Takeda Pharmaceutical Co Ltd | 1.08% | Equity (common) | JP |
| BMY | Bristol-Myers Squibb Co | 1.08% | Equity (common) | US |
| DHR | Danaher Corp | 1.08% | Equity (common) | US |
| RGEN | Repligen Corp | 1.06% | Equity (common) | US |
| NTLA | Intellia Therapeutics Inc | 1.06% | Equity (common) | US |
| TEM | Tempus AI Inc | 1.03% | Equity (common) | US |
| VKTX | Viking Therapeutics Inc | 1.00% | Equity (common) | US |
| DAR | Darling Ingredients Inc | 1.00% | Equity (common) | US |
| ABSI | Absci Corp | 0.99% | Equity (common) | US |
| VALU | Bayer AG | 0.98% | Equity (common) | DE |
| VALU | Zealand Pharma A/S | 0.93% | Equity (common) | DK |
| SANA | Sana Biotechnology Inc | 0.91% | Equity (common) | US |
Geographic Breakdown
Fund Holdings
WisdomTree BioRevolution Fund ·
NPORT-P period 2026-06-30
(filed 2026-02-27)
Net assets:
$3M
· 87 total positions
· equity 99.88%
· non-equity 6.99%
| # | Symbol | Issuer | Weight | Value |
|---|---|---|---|---|
| 1 | Structure Therapeutics Inc | Structure Therapeutics Inc | 3.21% | $81513 |
| 2 | Eli Lilly & Co | Eli Lilly & Co | 3.13% | $79526 |
| 3 | Natera Inc | Natera Inc | 2.93% | $74225 |
| 4 | Johnson & Johnson | Johnson & Johnson | 2.68% | $68087 |
| 5 | Moderna Inc | Moderna Inc | 2.66% | $67414 |
| 6 | Stoke Therapeutics Inc | Stoke Therapeutics Inc | 2.49% | $63226 |
| 7 | Pfizer Inc | Pfizer Inc | 2.42% | $61329 |
| 8 | United Therapeutics Corp | United Therapeutics Corp | 2.32% | $58957 |
| 9 | REGENXBIO Inc | REGENXBIO Inc | 2.30% | $58306 |
| 10 | BioNTech SE | BioNTech SE | 2.26% | $57215 |
| 11 | Amgen Inc | Amgen Inc | 2.21% | $55970 |
| 12 | Ionis Pharmaceuticals Inc | Ionis Pharmaceuticals Inc | 2.20% | $55693 |
| 13 | Amicus Therapeutics Inc | Amicus Therapeutics Inc | 2.19% | $55579 |
| 14 | Novo Nordisk A/S | Novo Nordisk A/S | 2.17% | $54979 |
| 15 | AstraZeneca PLC | AstraZeneca PLC | 2.15% | $54423 |
| 16 | Beam Therapeutics Inc | Beam Therapeutics Inc | 2.14% | $54193 |
| 17 | CRISPR Therapeutics AG | CRISPR Therapeutics AG | 2.09% | $53017 |
| 18 | Novonesis Novozymes B | Novonesis Novozymes B | 2.03% | $51491 |
| 19 | Immunome Inc | Immunome Inc | 1.85% | $47041 |
| 20 | Gilead Sciences Inc | Gilead Sciences Inc | 1.74% | $44186 |
| 21 | Exact Sciences Corp | Exact Sciences Corp | 1.59% | $40319 |
| 22 | Twist Bioscience Corp | Twist Bioscience Corp | 1.56% | $39682 |
| 23 | Arrowhead Pharmaceuticals Inc | Arrowhead Pharmaceuticals Inc | 1.54% | $38971 |
| 24 | Krystal Biotech Inc | Krystal Biotech Inc | 1.53% | $38707 |
| 25 | Novartis AG | Novartis AG | 1.52% | $38597 |
Showing top 25 of 85 equity holdings.
Non-equity holdings
— 2 positions,
6.99% of NAV
| Category | Weight | Value | Positions |
|---|---|---|---|
| Short-term investment | 6.99% | $177344 | 2 |
Price History
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -1.65% | 5 |
| Feb | -2.01% | 5 |
| Mar | -1.17% | 5 |
| Apr | -3.72% | 5 |
| May | -2.13% | 5 |
| Jun | +2.91% | 6 |
| Jul | +6.11% | 5 |
| Aug | -2.59% | 5 |
| Sep | -2.72% | 5 |
| Oct | -0.23% | 5 |
| Nov | +2.18% | 5 |
| Dec | -2.28% | 5 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $17.76
SMA 50: $17.89
SMA 200: $17.21
Current: $18.01
EMA 12: $17.89
EMA 26: $17.85
MACD: 0.0391 | Signal: 0.0075
BULLISH
ADX (14): 11.93
RANGE
+DI: 36.96
−DI: 28.21
Momentum Oscillators
RSI (14): 52.50
NEUTRAL
Stoch %K: 33.46
Stoch %D: 34.40
Williams %R: -59.94
Volume & Volatility
BB Upper: $18.55
BB Lower: $16.98
NEUTRAL
OBV: 33,847
Vol SMA 20: 996
Vol ROC: -91.00%
ATR: $0.46
True Range: $0.16
HV 20: 28.5%
HV 30: 25.2%
HV 60: 24.8%
Data Summary
Data Points: 500
Last Updated: 2026-06-12T21:15:27.221000
Date Range: 2024-06-14T00:00:00 – 2026-06-12T00:00:00
AI Analysis
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
Options Activity
- IV Rank (30D)
- 6.1
- IV Rank (7D)
- 99.24
- Avg IV
- 42.8%
- Straddle (30D)
- $2.00
- Straddle (7D)
- $1.32
- P/C Volume
- 0.00
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Volatility Surface
Enter a ticker to render the implied volatility surface.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.17
- Correlation (SPY)
- 54.7%
- R²
- 0.30
- Ann. Volatility
- 26.4%
- SPY Volatility
- 12.3%
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Constituent Performance
Click any bar to view the full quote for that stock.
Constituents
| Symbol | Price | 1 Day | 1 Week | 1 Month |
|---|